Awesome, thank you for that breakdown, the definit
Post# of 148155
(Total Views: 507)
Posted On: 05/29/2022 2:56:23 PM
Re: chuckles759 #123916
Awesome, thank you for that breakdown, the definitions and the timeline.
Therefore, we have agreed that CytoDyn should be following these patients at least until August 1, 2023, and at most up to November 7, 2023. I buy that.
But as to the dosing of LL, given the original statements made in the protocols of each trial, they would dose LL up to disease progression or up to intolerable toxicity.
So disease progression means that the cancer started up again. And Chris Recknor was calculating that based on CTC or numbers of metastasis. Therefore, if they measured increase in CTC, they may have decided that the disease had returned and stopped the dosing.
My OPINION: 16 of these patients came from the compassionate use trial and they were sick, they had failed 2 other treatment regiments. However, LL kept them alive and we made Overall Survivability of 12.5 months. Maybe LL put patient into remission as it reduced CTC's (metastasis) significantly.
Continuing, I'd say, that if CytoDyn had been giving LL as per schedule, given LL's capacity to immunomodulate the immune system back to normal, with NK cells actually killing, (rather than ignoring) metastasis and where T regulator cells, T helper cells, T cytotoxic cells, all return back to normal functioning, (not hypnotized and deluded by Tumor Overexpression of RANTES), so that the angiogenesis and vascularity supplying the Tumor dries up causing the Tumor to necrotize and die as well, I would therefore say, that these patients are still alive today and regardless if they constitute more than 1/2 of the 28. The rest remain alive as well.
I just hope CytoDyn kept the drug going and kept track of it all.
What are your thoughts?
Therefore, we have agreed that CytoDyn should be following these patients at least until August 1, 2023, and at most up to November 7, 2023. I buy that.
But as to the dosing of LL, given the original statements made in the protocols of each trial, they would dose LL up to disease progression or up to intolerable toxicity.
Quote:
Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 525 mg until disease progression or intolerable toxicity.
and
Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 350 mg until disease progression or intolerable toxicity.
So disease progression means that the cancer started up again. And Chris Recknor was calculating that based on CTC or numbers of metastasis. Therefore, if they measured increase in CTC, they may have decided that the disease had returned and stopped the dosing.
My OPINION: 16 of these patients came from the compassionate use trial and they were sick, they had failed 2 other treatment regiments. However, LL kept them alive and we made Overall Survivability of 12.5 months. Maybe LL put patient into remission as it reduced CTC's (metastasis) significantly.
Continuing, I'd say, that if CytoDyn had been giving LL as per schedule, given LL's capacity to immunomodulate the immune system back to normal, with NK cells actually killing, (rather than ignoring) metastasis and where T regulator cells, T helper cells, T cytotoxic cells, all return back to normal functioning, (not hypnotized and deluded by Tumor Overexpression of RANTES), so that the angiogenesis and vascularity supplying the Tumor dries up causing the Tumor to necrotize and die as well, I would therefore say, that these patients are still alive today and regardless if they constitute more than 1/2 of the 28. The rest remain alive as well.
I just hope CytoDyn kept the drug going and kept track of it all.
What are your thoughts?
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼